title: FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
abstract: Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and superior benefit/risk ratio to biopsy of two combinations of simple serum biochemical markers in patients infected with hepatitis B and C virus. These include FibroTest (BioPredictive) for the quantitative assessment of fibrosis, and ActiTest (BioPredictive) for the quantitative assessment of necroinflammatory activity (HCV-FibroSURE, LabCorp). The possible causes of false negatives and positives are also better identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases.
authors.affiliation: Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. tpoynard@teaser.fr
authors.forename: Thierry
authors.initials: T
authors.lastname: Poynard
authors.forename: Françoise
authors.initials: F
authors.lastname: Imbert-Bismut
authors.forename: Mona
authors.initials: M
authors.lastname: Munteanu
authors.forename: Vlad
authors.initials: V
authors.lastname: Ratziu
mesh_terms: D015415:Biomarkers / Q000097:blood; D019411:Clinical Laboratory Techniques / Q000191:economics; D003933:Diagnosis; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis*
chemical_list: D015415:Biomarkers